KURA250117C22500
- 0.10
- 0.000.00%
Kura Oncology Newsroom
Kura Oncology's Stock Sinks To US$8.94, But Insiders Sold Even Lower
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $30
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $37
Jonathan Chang Recommends 'Buy' on Kura Oncology Amid Promising Ziftomenib Advancements in AML Treatment
Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Kura Oncology (KURA)
Express News | Cantor Fitzgerald Reiterates Overweight on Kura Oncologyto Overweight
Kura Oncology Analyst Ratings
Kura Oncology Provided Clinical Data From KOMET-007 Phase 1 Dose-escalation Trial Of Ziftomenib In Combination With Standards Of Care For NPM1-mutant And KMT2A-rearranged Acute Myeloid Leukemia
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
BofA Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Announces Target Price $29
Barclays Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $32
Kura Oncology Holds a Pharmaceutical Update Conference Call
BofA Securities Maintains Kura Oncology(KURA.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Cooper Co (COO) and Ironwood Pharma (IRWD)
Kura Oncology Management to Meet With Cantor Fitzgerald
Jefferies Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28
Jefferies Sticks to Its Buy Rating for Kura Oncology (KURA)
Kura Oncology to Host Virtual Investor Event on KOMET-007 Trial of Ziftomenib Following ASH Annual Meeting
Kura Oncology to Host Virtual Investor Event on December 9, 2024
Express News | Cantor Fitzgerald Reiterates Overweight on Kura Oncology